Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

You could pay about $171 per month for Mounjaro if you use a discount from the drug maker, Lilly, on top of insurance benefits ... can't get free Mounjaro through the drug maker's patient assistance ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...

Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...

executive vice president and president of Lilly Oncology. "The selectivity profile of STX-478 has led to a differentiated clinical profile, enabling use in combinations with standard-of-care therapies ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...